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Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis 
ABSTRACT 
Introduction:  Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in 
significant disability.  With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic 
outcomes in PsA have improved substantially.  The clinical efficacy and the inhibition of 
radiographic progression demonstrated by TNFi have transformed the management of PsA.  
However, there is still an unmet need for a subset of patients who do not respond adequately to 
TNFi.   
Areas Covered:  This review provides an overview of the pharmacokinetics of TNFi, the efficacy 
of TNFi in PsA, and the role of immunogenicity of TNFi in the treatment of PsA. In addition, we 
address the use of TNFi in the setting of other medications utilized in the treatment of PsA and 
the potential future role of biosimilars. 
Expert Commentary:  Monoclonal antibodies exhibit complex and widely variable 
pharmacokinetics.  The study of factors that can affect the pharmacokinetics, such as 
immunogenicity, is valuable to further define and understand the use of TNFi in PsA, especially 
in the subset of patients who do not respond adequately to these agents or lose effectiveness over 
time. 
   
 
 
 
  
1. Introduction 
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints, periarticular 
structures, skin, and nails.  The disease can result in permanent joint damage and disability. The 
prevalence of PsA ranges from 0.06% to 0.25% in developed countries such as the US, UK, and 
Western Europe.  It is common among patients with psoriasis with a prevalence ranging from 6-
41% [1]. Treatment of PsA has evolved substantially since the 1990s with introduction of the 
tumor necrosis factor inhibitors (TNFi).  This review will focus on the pharmacology and clinical 
efficacy of the TNFi in PsA.   
2. Psoriatic Arthritis 
2.1 Clinical Manifestations 
PsA is a heterogeneous condition encompassing a wide range of clinical manifestations that 
include the key domains of peripheral and axial arthritis, inflammation at tendon/ligament 
insertion sites (enthesitis), diffuse swelling of an entire finger or toe (dactylitis), nail disease, and 
psoriasis [2].  The incidence and prevalence of cardiovascular disease and diabetes is increased 
in PsA [3].  Inflammatory bowel disease and ophthalmic disease, particularly uveitis, are 
considered extra-articular manifestations of the disease [3-4].  
2.2 Risk Factors 
Although PsA can occur prior to developing psoriasis, psoriasis usually precedes PsA in the vast 
majority of patients by approximately 10 years [5-6].  Obesity has been associated with an 
increased risk of developing PsA not only in patients with psoriasis, but also among patients in 
the general population [7-8].  Nail disease has been suggested as a potential risk factor for PsA 
but may also be just an early feature of the disease [1].  Intergluteal/perianal psoriasis, and scalp 
lesions in psoriasis patients may be associated with a greater likelihood of developing PsA [9].  
Other potential associations include a family history of PsA and severe psoriatic dermatoses [10-
11]. 
2.3. Importance of Early Diagnosis 
Early diagnosis of PsA is crucial for prevention of disease progression [12] and may also 
influence development of comorbidities.  Early PsA has been defined as within one to two years 
of the onset of symptoms [13].  Erosions and worse long term physical outcomes have been 
demonstrated with even a six-month delay in diagnosis [14-17].  Unlike conventional synthetic 
disease modifying antirheumatic drugs (csDMARDs), TNFi have been demonstrated to prevent 
or slow radiographic progression of PsA.  Early institution of therapy within 6 months of disease 
initiation results in improved response to therapy and improved long term outcomes [12, 18].      
2.4. Treatment 
The most widely used consensus treatment recommendations are The Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European League Against 
Rheumatism (EULAR) recommendations (Figure 1 & 2).  Overarching principles of therapy are 
similar, and include shared decision making with the patient, controlling symptoms and 
preventing damage, improving quality of life, minimizing or avoiding complications, and 
assessing comorbidities.  A central feature in the treatment of PsA is considering all the domains 
involved when deciding on a treatment regimen.  The GRAPPA and EULAR recommendations 
favor a “step-up” approach for the treatment of PsA [4,19].  NSAIDS and intra-articular 
corticosteroids may be effective in reducing pain from inflammation.  Traditional oral therapies 
such as methotrexate (MTX), leflunomide (LEF), and sulfasalazine (SSZ) can decrease 
inflammation and improve symptoms.  Both NSAIDS and csDMARDs are commonly used in 
PsA, but neither treat all domains of the disease. Other than the TICOPA study, a treat to target 
study in PsA [20], there is little data confirming the efficacy of MTX in PsA [21-23].  However, 
csDMARDS, particularly MTX, continue to be a mainstay of treatment even though they have 
not been shown to clearly inhibit radiographic progression and there is a paucity of efficacy data. 
MTX remains the most commonly used therapy for PsA and has good retention rates (e.g, 2-year 
retention rates of 65%, Lie et al. in 2010 [24]).  The GRAPPA recommendations do not 
specifically delineate MTX as the csDMARD of choice or TNFi as the first biologic DMARD 
(bDMARD) of choice [4].  TNFi are the first line bDMARD of choice in the EULAR 
recommendations on the basis of clinical data and evidence of efficacy and long-term safety data 
that is available compared to other biologic agents, such as the IL-17A inhibitor, secukinumab, 
and the IL-12/23 inhibitor, ustekinumab [19].  Furthermore, the TNFi have been shown to inhibit 
progressive joint destruction and are an effective treatment for all domains of the disease [25].  
As there is a paucity of data on axial disease in PsA, recommendations are derived from data for 
axial spondyloarthritis [26-30].  Both organizations recommend bDMARDs after NSAID failure 
for axial disease and enthesitis as csDMARDs are not efficacious in these two disease domains 
[4,19].  A distinction between the two sets of recommendations is that GRAPPA 
recommendations allow for an “expedited therapeutic route” in which csDMARDs are bypassed 
and a bDMARD may be initiated early.  This recommendation is based on a) the efficacy of 
bDMARDS and relatively little data for traditional oral agents for long term prevention of 
progression and b) the relative lack of efficacy of oral agents for enthesitis, both particularly in 
the patient with poor prognostic factors (e.g., elevated C-reactive protein or high joint counts) 
[4].   
2.4.1 Defining Treatment Response 
The primary outcome used in PsA randomized controlled trials (RCTs) is the American College 
of Rheumatology (ACR)-20% improvement criteria.  Patients must achieve at least a 20% 
improvement in the tender and swollen joint counts and at least three of the five remaining 
outcome measures: Health Assessment Questionnaire-Disability Index, Patient pain assessment, 
Patient global assessment, Physician global assessment, C-reactive protein.  Psoriasis severity is 
measured in RCTs using the Psoriasis Area and Severity Index (PASI) score.  The PASI75 is an 
improvement of at least 75% in the PASI score [31].  PASI75 (or even PASI90) is generally a 
secondary outcome in RCTs examining therapies for PsA. While ACR20 and PASI are the most 
commonly used outcome measures in trials, these measures are not often used in clinical 
practice.  Instead a variety of outcome measures are used including joint counts, enthesitis 
measures, dactylitis assessment, psoriasis severity, and patient reported outcomes [6, 32].   
3. Tumor Necrosis Factor  
In 1975, TNF was recognized as an endotoxin-induced glycoprotein that caused hemorrhagic 
necrosis of transplanted sarcomas in mice [33].  Since then, it has been associated with a wide 
range of biologic conditions and has been identified as an important pro-inflammatory cytokine 
[34].  Overexpression of TNF has been implicated in the pathogenesis of a wide variety of 
diseases, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and PsA [35-36].  
TNF is a pleotropic cytokine that is produced by cells such as activated macrophages, T 
lymphocytes, monocytes, neutrophils, mast cells, endothelial cells, fibroblasts, and osteoclasts.  
It is a key driver of many inflammatory activities in the body and also contributes to cell 
proliferation, apoptosis, and angiogenesis [35, 37].  Transmembrane TNF (tmTNF), a 26 kDa 
protein, is cleaved by a metalloproteinase, TNF-alpha-converting enzyme (TACE), and is 
ultimately released as a soluble cytokine, sTNF (17kDa) [34, 38-40].  sTNF and tmTNF can then 
bind to TNF receptor 1 (TNFR1, p55) or TNF receptor 2 (TNFR2, p75) and exert biological 
effects on various cell types [34, 38].  TNFR1 and TNFR2 use different signaling mechanisms; 
they have differing affinities to ligands and distinct cellular expression profiles [38].  These 
differences may contribute to varied biological responses [34, 41].   
4. Role of TNF in the Pathogenesis of PsA (Figure 3) 
While genetic and environmental factors may play a role in the development of PsA, the immune 
response to such triggers is what sustains the disease. Inflammation in PsA is thought to be 
driven both by the Th1 and Th17 pathways. In both pathways, TNF superfamily proteins 
are important for sustaining inflammation [42].  When the inciting antigen is presented to the 
initial T-cell, unregulated IL-12 causes differentiation and propagation of Th1 cells and 
contributes to the release of pro-inflammatory cytokines, including TNF [43].  Conversely, IL-23 
is thought to play a key role in the pathogenesis of PsA by triggering Th17 cell differentiation 
[44].  This leads to production of IL-22 and IL-17.  IL-17 leads to upregulation of TNF [45].  
TNF, along with several other cytokines, induces expression of receptor activator of nuclear 
factor-κB ligand (RANK-L), a member of the TNF superfamily, promoting 
osteoclastogenesis and eventually erosion formation [46]. TNF also induces expression of 
Dickkopf-related protein 1 (Dkk-1) by synovial fibroblasts, inhibiting osteoblastogenesis, further 
promoting erosions [46].   
5. TNF Inhibitors 
Etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab are the TNFi that have 
been approved for PsA in the US and UK.  Etanercept was the first FDA approved TNFi for the 
treatment of PsA in January 2002.   
5.1 Structure and Mechanism of Action of TNFi  
TNFi are monoclonal antibody therapeutics directed at TNF.  IgG monoclonal antibodies are 
large proteins that possess hydrophilic properties [48].  They consist of two unique heavy chains 
and two unique light chains each of which has constant and variable domains [48].  The heavy 
and light chains are linked by disulfide bonds and connected by disulfide bonds at the hinge 
region to a fragment crystallizable (Fc) region [49].  The fragment antigen-binding region (Fab) 
is the antigen-binding portion and the Fc region is the portion which takes part in Fc mediated 
actions, such as complement-dependent cytotoxicity and antibody-dependent cell mediated 
cytotoxicity [50].   The Fc portion also binds to the neonatal Fc receptor (FcRn), which is 
integral in protecting the antibody from intracellular catabolism [49, 51].  The hypervariable 
region at the top of the variable domain is where binding to the target antigen occurs [48-49].   
 
With the exception of certolizumab and etanercept, the remaining three TNFi are full-length 
bivalent monoclonal antibodies (mAB) [38] (Figure 4).  Certolizumab is a humanized (exogenic 
hypervariable regions) IgG1 monoclonal antibody with a Fab1 fragment [38, 48]. The hinge 
region is modified and is linked to polyethylene glycol allowing for better solubility, half-life, 
bioavailability, and decreased immunogenicity.  It has an affinity for both sTNF and tmTNF 
[52].  Unlike the other TNFi, certolizumab does not have an Fc portion and therefore does not 
take part in Fc mediated actions [50].  In contrast to the other TNFi, etanercept is a genetically 
engineered soluble fusion protein that is composed of two extracellular portions of the p75 TNF 
receptor linked to the Fc portion of human IgG1 [38].  It binds to both sTNF and tmTNF at the 
receptor binding site, preventing the binding of TNF with the p75 receptor [38, 53].  The short 
half-life of entanercept may in part be due to a difference in the conformation of the Fc region 
[38].  In addition, etanercept is the only TNFi of the five that also binds members of the 
lymphotoxin (LT) family (also members of the TNF superfamily), specifically LTα3 and 
LTα2β1 [38].  Infliximab is unique in that it is a chimeric IgG1k mouse and human monoclonal 
antibody that consists of human constant regions of IgG1k and murine variable regions [38, 54].  
It binds to both sTNF and tmTNF with high affinity via the E-F loop, blocking the ability of TNF 
to bind to its receptors [55].  Adalimumab is a recombinant human IgG1 antibody.  It occupies 
the TNF receptor-binding site of both sTNF and tmTNF with high affinity, preventing the 
binding of TNF to its receptors [54-55].  Like adalimumab, golimumab is a human 
immunoglobulin IgG1 monoclonal antibody that binds to both sTNF and tmTNF [38, 56].   
(Table 1) 
5.2 General Pharmacokinetic Properties of TNFi 
5.2.1 Absorption 
As large protein molecules with poor membrane permeability, TNFi are administered 
parenterally.  The oral bioavailability is very low as they are denatured in the acidic environment 
of the stomach or they undergo a rapid proteolytic cleavage in the GI tract [49, 57].  It is 
hypothesized that monoclonal antibodies are absorbed via the lymphatic system by convection 
and diffusion across blood vessels [49, 51].  Absorption can take anywhere from about one to 
eight days [58].  Most of the TNFi are administered subcutaneously (infliximab is intravenous 
only and golimumab can be given IV or subcutaneously), which can cause variability among 
patients in regards to the amount of drug absorbed [59].   
5.2.2 Distribution 
Given their large weight and hydrophilic nature, monoclonal antibodies usually have a small 
volume of distribution [49].  The molecules usually reside in the vascular and interstitial spaces 
and are distributed via paracellular movement by convection and via transcellular movement by 
endocytosis (phagocytosis, receptor-mediated endocytosis, or fluid-phase pinocytosis) [49, 51].  
Convective transport is driven by the blood-tissue hydrostatic pressure gradient.  Osmotic 
pressure gradients and the characteristics of the paracellular pores also affect convective 
transport [58].  
5.2.3 Metabolism and Excretion 
Since monoclonal antibodies are large molecules, they are not predominantly renally excreted.  
The PEG portion of certolizumab decreases its renal excretion secondary to increasing the size of 
the molecule [52].  Very little is also excreted in bile [49, 51].  These molecules undergo 
catabolic metabolism via Fc-receptor mediated elimination and target mediated elimination 
(clearance following binding to target) [49].  The Fc portion is also thought to contribute to the 
long half-life of most of these monoclonal antibodies since it interacts with the FcRn, which has 
a mechanism that protects these molecules from systemic elimination [60]. (Table 2) 
5.3 Pharmacokinetics of TNFi 
TNFi differ in their pharmacokinetic (PK) properties. Underlying disease type or severity, body 
weight, immunogenicity, and the concomitant use of other medications such as MTX can impact 
PK parameters. Elimination of TNFi for the treatment of PsA generally follows linear kinetics 
and volume of distribution is that of the central compartment (~6 L). [48, 61-66].  Table 3 
outlines the pharmacokinetics of monoclonal antibodies utilized in rheumatic diseases with an 
emphasis, when available, on population pharmacokinetic parameters in PsA. 
5.3.1 Obesity 
Obesity impacts the pharmacokinetics of TNFi.  Higher disease activity is seen in obese PsA 
patients and disease registries suggest obesity is associated with a decreased response to TNFi 
[78].  PsA patients on TNFi that lost >5% from their baseline weight were found to be 
significantly more likely to achieve minimal disease activity (MDA) than patients who did not 
lose weight [79].  Obesity may affect the pharmacokinetics of TNFi secondary to insufficient 
dosing, changes in volume of distribution, and increased drug elimination. [48, 78]. 
5.3.2 Immunogenicity 
Immunogenicity, the ability of a substance to cause an immune response [49], can play a role in 
the varying pharmacokinetics of monoclonal antibodies.  The underlying disease, duration of 
treatment, route of administration, concomitant medications, dose frequency, genetic 
predisposition, assay methodology, and the type of antibody can all affect the immunogenicity of 
TNFi [80-82].  Humanization of monoclonal antibodies may help to decrease immunogenicity 
[48, 51].  Thus, the chimeric structure of infliximab can account for its high immunogenicity 
potential.  A meta-analysis of TNFi immunogenicity in RA, inflammatory bowel disease, and 
spondyloarthritis (PsA and ankylosing spondylitis) among patients using one of the five TNFi 
demonstrated infliximab was the most and etanercept the least immunogenic [83].  There is 
sparse data regarding the extent of immunogenicity of golimumab and certolizumab in PsA. 
The elimination rate of TNFi is impacted by immunogenicity.  Anti-drug antibodies will increase 
the elimination rate of TNFi [48, 67, 75, 80].  They may form immune complexes with the drug 
accelerating its clearance [84].  Small studies have demonstrated a correlation between anti-
adalimumab antibodies and decreased serum concentration and thus decreased clinical response 
[85-86].  Another small study demonstrated elevated levels of anti-drug antibodies to 
adalimumab and infliximab, but not etanercept in PsA patients, which correlated with low 
therapeutic drug levels and thus decreased drug efficacy [87].  
5.3.3 Concomitant use of MTX and Immunogenicity 
There is an association between MTX, a widely used therapy in PsA, and the development of 
anti-drug antibodies.  A meta-analysis by Thomas et al showed that MTX can attenuate the 
formation of antibodies by 74% overall and antibodies decreased clinical response by 18% 
overall in SpA (based on 4 studies looking at infliximab, adalimumab, and etanercept [83].  In 
RCTs of infliximab and golimumab, a greater proportion of patients on TNFi monotherapy were 
positive for antibodies compared to those taking concomitant MTX [88-89].  However, efficacy 
of TNFi is not generally impacted by MTX use [88-94].  Interestingly, a post-hoc analysis 
determined that patients who were taking combination MTX and golimumab had a ten percent 
greater improvement in nail, dactylitis, and enthesitis scores compared to those not taking MTX 
[89]. In an observational cohort study of 375 patients with RA or PsA treated with adalimumab, 
trough concentrations were higher in patients concomitantly taking MTX and lower in patients 
on adalimumab monotherapy [95].  
6. Key Clinical Trials of TNFi in PsA 
TNFi in PsA were found to be efficacious with tolerable safety profiles in pivotal phase III trials 
(Table 4).  The most common adverse events include injection site reactions, infusion reactions 
in infliximab, and infections [6].  All five TNFi demonstrated an inhibition in radiographic 
progression.  In the GO-REVEAL 5-year study, concomitant MTX appeared to reduce 
radiographic progression [91].  Only the certolizumab trials included patients who were exposed 
to TNFi previously (19.8% of patients).  Interestingly, improvements in ACR 20 response rates 
at 12, 24, and 96 weeks were observed for both doses regardless of prior TNFi exposure [93, 96].  
7. Other Treatment Options for PsA 
A number of patients do not respond to TNFi and many more have a loss of response over time.  
Thus, recognition of the IL-23/IL-17 pathway in the pathogenesis of PsA and molecules that are 
targeting other cytokines in the pathway have been integral to the development of further 
medications to treat PsA.  
7.1 Apremilast 
Apremilast is an oral phosphodiesterase 4 inhibitor (PDE-4i) that is approved for the treatment of 
PsA.  PDE4 mediates the breakdown of cAMP, which regulates inflammatory responses. Thus, 
PDE4 inhibitors demonstrate anti-inflammatory effects [103]. The clinical efficacy of apremilast 
in PsA patients who have already been treated with csDMARDS and/or bDMARDS or are on 
csDMARDS was studied extensively with several pivotal randomized placebo-controlled trials 
(Table 5).  In the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) 
phase III trials, in PALACE 1, 2, and 3, the primary endpoint, an ACR20 response at week 16, 
was achieved by significantly more patients taking apremilast 20 mg or 30 mg bid as compared 
to placebo regardless of prior treatment.  bDMARD-naïve patients had higher ACR20 response 
rates [104-106].  Sustained improvements were seen through week 52 in PALACE 1, 2, and 3. In 
PALACE 4, patients who were DMARD-naïve were studied over a 52-week period.  The 
primary end point was met for both doses at weeks 16 and 52 [107]. Studies suggested a lack of 
efficacy of apremilast in axial disease [108-109].  The most common adverse events were 
diarrhea and nausea [104-107].   
7.2 Secukinumab 
Secukinumab is a human IgG1 monoclonal antibody that binds to and neutralizes IL-17A.  
FUTURE 1 and 2 are key phase III, randomized, double-blind, placebo-controlled trials that have 
demonstrated the efficacy of secukinumab in the key domains of PsA (Table 5) [110-111].  
MEASURE 1 and 2 are key phase III, randomized, double-blind, placebo-controlled trials that 
have demonstrated the efficacy of secukinumab in ankylosing spondylitis and thus should be 
effective for axial disease in PsA [112].  Additionally, secukinumab has been shown to decrease 
radiographic progression [110].  Efficacy was noted regardless of concomitant MTX use and 
among patients with prior TNF exposure, though the response was lower.  Generally, 
numerically higher ACR responses were noted in the anti-TNF naïve populations.  Efficacy was 
sustained through week 52.  Candida infections were more common in secukinumab versus 
placebo, which may be because IL-17 plays a role in host defense again fungal infections [110-
111].   
7.3 Ustekinumab 
Ustekinumab inhibits IL-12 and IL-23 by binding to the p40 subunit of IL-12 and IL-23.  
PSUMMIT 1 and PSUMMIT 2 are pivotal phase III, double-blind, placebo-controlled trials that 
studied ustekinumab in PsA patients and found that there was a significant improvement in joint 
and skin disease and less radiographic progression compared to placebo (Table 5).  In 
PSUMMIT-1, ACR20 response rates were maintained at week 52 and efficacy was noted 
regardless of MTX use [113].  In contrast to PSUMMIT-1, in PSUMMIT-2, 58% of patients had 
been on TNFi previously. Clinical improvement was noted regardless of prior TNF exposure but 
was again lower (as has been seen in other studies of TNF inadequate responders).  Anti-TNF-
naive patients appeared to have a higher clinical response than anti-TNF-experienced patients 
[114].  Phase III, randomized, double-blind, placebo-controlled trials are underway to evaluate 
the efficacy and safety of ustekinumab in ankylosing spondylitis [117-118].  Ustekinumab has a 
tolerable safety profile with a low incidence of serious infections and sustained clinical 
improvement through week 100 [115]. 
8. Expert Commentary 
PsA is a heterogeneous, often debilitating disease that is associated with several comorbidities.  
Early intervention is vital to prevent disease progression.  Although csDMARDS show variable 
efficacy in PsA [19,22], they have remained key medications in treatment largely in part due to 
cost considerations.  With the emergence of TNFi, treatment options have vastly expanded for 
PsA patients.  TNFi inhibit radiographic progression and are effective in treating all the domains 
of PsA [25].  However, some patients do not respond to TNFi or response may wane over time.  
Thus, the emergence of IL-17A inhibitors, IL-12/23 inhibitors, and small molecule treatments 
such as apremilast have provided a wider range of therapeutic options for PsA.  Although 
apremilast has the advantage of being an oral medication with a relatively benign side effect 
profile, its effect on radiographic progression has not been examined.  The TNFi agents 
etanercept, infliximab, adalimumab, and golimumab appear to have ACR20 advantage over 
newer non-TNFi biologics such as apremilast and ustekinumab, when compared using indirect 
methods [119].  There are no direct comparative efficacy trials between non-TNFi biologics, 
however indirect comparisons suggest similar efficacy and safety among available agents [120].   
There are also several new medications that are currently being evaluated for the treatment of 
PsA (Table 6).   
Even though there is an emergence of many new therapies in PsA, there is a subset of patients 
that do not adequately respond to available treatments.  Thus, it would be of benefit to further 
study established therapies in PsA such as TNFi by assessing parameters that affect drug 
concentrations in this patient population.  Given that monoclonal antibodies exhibit complex and 
widely variable pharmacokinetics, further population PK studies in PsA would be helpful in 
identifying covariates, such as age, immunogenicity, weight, comorbidities, and concomitant 
medications, which can influence dose-concentration-effect relationships [80].  Outside of 
weight based dosing adjustment, individualization of dosing is currently not the standard for 
monoclonal antibodies in autoimmune disease. A model based approach that links monoclonal 
exposure with disease state may eventually allow for more individualized dosing based upon 
disease phenotype, endotype (biomarker driven) and potentially, though less likely, genotype. In 
addition to drug concentrations, anti-monoclonal drug antibody levels can play a role on the 
effect of treatment discontinuation and adverse events such as infusion reactions, which have 
occurred at a higher incidence in antibody positive patients [81, 88].  It can provide insight into 
whether or not switching to another TNFi or a medication with a different mechanism of action 
in patients with poor clinical outcomes would be of greater benefit.  Thus, having a better 
understanding of the factors associated with inter-individual variability and the extent of that 
variability may eventually contribute to potential dosing strategies that can improve clinical 
outcomes, especially in patients with TNFi failure. 
While combination treatment may be common in clinical practice, there is little data regarding its 
clinical efficacy [4, 19].  However, decreased immunogenicity of TNFi with concomitant MTX 
may play a role in improving drug survival rates of TNFi [121-122].  In addition, one study 
noted higher drug levels in a small group of 26 patients on adalimumab combination therapy 
(with csDMARDS such as LEF, SSZ, or HCQ) compared to patients using adalimumab 
monotherapy [95].  Prospective, randomized clinical trials of TNFi with various csDMARDs to 
assess trough antibody drug concentrations, anti-drug antibody levels, the measurement of a 
clinical response (ACR 20 response), and to further assess the potential long term side effects of 
combination therapy in PsA would be of value. 
9. Five-year View 
With further understanding of the pathogenesis of PsA, novel treatment options are emerging.  
Over the last several years, many effective therapeutic options have been introduced and more 
are yet to come.  Biosimilars, which are products similar to already approved drugs in regard to 
quality, safety, and efficacy [123], may help to alleviate the economic burden associated with 
TNFi.  Few studies have evaluated infliximab, etanercept, and adalimumab biosimilars for PsA.  
These agents have been approved in the United States for PsA based on similar efficacy to the 
reference product in psoriasis and/or RA [123-124].  Immunogenicity has been the same, and in 
some cases less than reference products [125]. Switching established patients in ankylosing 
spondylitis and rheumatoid arthritis from infliximab to the biosimilar product CP-P13 is not 
associated with a loss of control [126-127].  Extrapolation from other disease states is 
complicated if alternate dosing regimens are used. RCTs or pragmatic trials specific to PsA may 
provide beneficial information regarding the efficacy and safety of biosimilars, but with current 
evidence the use of biosimilars in established or de novo patients appears to reasonable.  Similar 
to their reference products, trials evaluating how the combination of a biosimilar with a 
csDMARD affects immunogenicity would be of interest.  Long-term pharmacoepidemiology 
studies assessing predictors of response to biosimilars and the effectiveness of switching from 
the reference product to a biosimilar and vice versa will provide valuable information. 
Key Issues 
• Psoriatic Arthritis is a chronic, debilitating disease associated with several comorbidities. 
• TNFi are a mainstay of treatment in PsA and inhibit radiographic progression. 
• Several factors affect the pharmacokinetic properties of TNFi, including underlying 
disease type or severity, body weight, immunogenicity, and the concomitant use of other 
medications such as MTX. 
• Identifying drug concentrations and anti-monoclonal drug antibody levels may help more 
quickly identify patients with TNFi failure and may provide insight regarding medication 
changes.  
• Assessing the effect of combination csDMARDS and TNFi on immunogenicity may 
contribute to future treatment recommendations.  
• While not tested specifically in PsA, biosimilars are expected to have similar efficacy and 
safety to reference products.  
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FIGURES 
 
Figure 1.  Simplified GRAPPA Treatment Recommendations [4] 
*combination csDMARDS and TNFi common in clinical practice 
**Conditional recommendations: At the time these recommendations were published, these drugs 
were not approved or recommendations were based on data from abstracts 
csDMARD, conventional synthetic DMARD; CSA, cyclosporin A; GRAPPA, Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis; IL-17i, interleukin-17 inhibitor; 
IL-12/23i, interleukin-12/23 inhibitor; LEF, leflunomide; MTX, methotrexate; NSAIDS, 
nonsteroidal anti-inflammatory drugs; PDE-4i, phosphodiesterase 4 inhibitor; SSZ, sulfasalazine; 
tsDMARD, targeted synthetic DMARD; TNFi, tumor necrosis factor inhibitor 
 
Figure 2. Simplified EULAR Treatment Recommendations [19]  
*bDMARD includes TNFi, IL-12/23i, IL-17i.  The preference initially is a TNFi, but if 
contraindicated, can consider one of the others or a PDE-4i. 
**no adverse prognostic factors: can try a second csDMARD or combination therapy 
bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; CI, 
contraindicated; EULAR, European League Against Rheumatism; IL-17i, interleukin-17 
inhibitor; IL-12/23i, interleukin-12/23 inhibitor; LEF, leflunomide; MTX, methotrexate; 
NSAIDS, nonsteroidal anti-inflammatory drugs; PDE-4i, phosphodiesterase 4 inhibitor; SSZ, 
sulfasalazine; tsDMARD, targeted synthetic DMARD; TNFi, tumor necrosis factor inhibitor 
 
Figure 3. Pathogenesis of Psoriatic Arthritis 
The Th1 and Th17 pathways are important pathways involved in the pathogenesis of PsA.  TNF, 
a pro-inflammatory cytokine, is a key player in osteoclastogenesis via RANK-L and in inhibition 
of osteoblastogenesis via Dkk-1.  Both processes eventually lead to bone erosions [46].  In 
addition, IL-22 is involved in the pathologic formation of new bone (osteoproliferation) [47].   
APC, antigen presenting cell; Dkk-1, dickkopf-related protein 1; IFNγ, interferon gamma; IL-12,  
interleukin-12; IL-17, interleukin-17; IL-22, interleukin-22; IL-23, interleukin-23; RANK-L, 
receptor activator of nuclear factor-κB ligand; T cell, T lymphocyte; Th1, type 1 T helper cell; 
Th17, T helper 17 cell; TNF, tumor necrosis factor 
 Figure 4. Simplified structures of TNFi  
Fab, fragment antigen-binding; Fc, fragment crystallizable region; IgG1, immunoglobulin G1; 
PEG, polyethylene glycol; TNF, tumor necrosis factor; TNFR2, tumor necrosis factor receptor 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables 
Table 1.  Basic Characteristics of TNFi  
TNFi Structure Protein Type Affinity Fc Portion? 
Infliximab 
Full length bivalent 
mAb 
Chimeric & 
Human 
sTNF & tmTNF Yes 
Etanercept 
Genetically engineered 
Fc-fusion protein 
Recombinant 
Human 
sTNF, tmTNF, 
LTα3, LTα2β1 
Yes 
Adalimumab 
Full length bivalent 
mAb 
Fully Human sTNF & tmTNF Yes 
Golimumab 
Full length bivalent 
mAb 
Fully Human sTNF & tmTNF Yes 
Certolizumab 
Pegol 
 
Monovalent Fab1 
antibody fragment 
 
Humanized 
 
sTNF & tmTNF 
 
No 
 
Fab, fragment antigen-binding; Fc, fragment crystallizable region; LTα3, lymphotoxin alpha 3; 
LTα2β1, lymphotoxin alpha 2 beta 1; mAb, monoclonal antibody; sTNF, soluble tumor necrosis 
factor; tmTNF, transmembrane tumor necrosis factor; TNFi, tumor necrosis factor inhibitor  
  
  
  Table 2.  General Pharmacokinetic Properties of Monoclonal Antibodies 
 
Absorption 
 
 
Lymphatic system via convection & 
diffusion 
 
 
Distribution 
 
 
Small volume of distribution, 
paracellular and transcellular movement 
 
 
Metabolism and Excretion 
 
 
Catabolic metabolism 
 
 
  
Table 3 Pharmacokinetics of TNFi in Rheumatologic Diseases  
 Infliximab Etanercept c Adalimumab Golimumab Certolizumab 
Administration IV SC SC SC SC 
Loading Dose 3-5 mg/kg at 0,2, 
and 6 wks 
- - - 400 mg at 0,2, 
and 4 wks  
Maintenance 
Dosages 
3-10 mg/kg every 4-
8 wks  
50 mg weekly 40 mg eow  50 mg once 
a month  
200 mg eow 
or 400 mg 
once a month  
Half-life (t1/2) 8-10 days 
a 3-5 days  14 days  14 days d 
 
14 days  
Clearance (L/d) 0.26b 
 
1.67  
 
0.269  
 
0.40d 0.408  
 
Bioavailability -  58%  64%  53%  80%  
Cmax μg/ml 192 ± 51b  2.4 ± 1.5  4.7 ± 1.6  2.5  
 
43-49 (after 
loading dose)  
References [38,64,67-70] [53,65,70,72-73] [65,70,75] [61,76] [65-66] 
a Population PK in PsA for infliximab:  The t1/2 life was 15.7 days [71]  
b based on 5 mg/kg IV in RA patients  
c PK of etanercept 50 mg once weekly is comparable to 25 mg twice a week SC [74]  
d Population pharmacokinetics in PsA were characterized using a 1-compartment 
model.  Clearance:  0.68 L/d, t1/2 life of golimumab was 12.5 days [77] 
eow, every other week; SC, subcutaneous; IV, intravenous; TNFi, tumor necrosis factor 
inhibitor; wk, week 
  
  Table 4. Pivotal Phase III Trials of TNFi in Psoriatic Arthritis 
 
 Reference Study 
Size 
(n) 
 
Doses (vs 
Placebo) 
% Achieving 
ACR20 Response  
(tx/placebo) 
(primary endpt wk) 
% Achieving 
PASI75 Response  
(tx/placebo)  
(primary endpt wk) 
 
 
Inhibition of 
Radiographic 
Progression 
 
Infliximab 
 
IMPACT [97-
98] 
 
104 5 mg/kg IV 
 
65.4/9.6 (16) 
 
68/0 (16) 
 
50 wks  
 
 
 
IMPACT 2 
[99-100] 
 
200 5 mg/kg IV 
 
58/11 (14) 64/2 (14) 
 
6 months and 1 yr  
Etanercept 12 wk study 
[101]  
 
60 25 mg SC 2x wk 
 
73/13 (12) 
 
26/0 (12) 
 
Not studied 
 24 wk study 
[94,102]  
205 25 mg SC 2x wk 59/15 (12) 
 
- 12 months & 2 yrs  
Adalimumab ADEPT [92]  
 
313 40 mg SC eow 
 
58/14 (12) 
 
- 24 wks 
 
Golimumab* GO-REVEAL 
[90-91]  
 
405 
 
50 mg/100 mg  51/45/9 (14) 
 
40/58/3 (14) 
 
24 wks & 256 wks  
 
 
Certolizumab** RAPID-PsA 
[93,96]  
 
409 200 mg/400 mg  58/51.9/24.3 (12) 
 
46.7/47.4/14 (12) 
 
96 wks  
 
ACR20, American College of Rheumatology 20% improvement criteria; endpt, endpoint; eow, every other week; IV, intravenous; 
PASI75,  75% improvement in Psoriasis Area and Severity Index; SC, subcutaneous; tx, treatment; TNFi, tumor necrosis factor 
inhibitor; wk, week; yrs, years 
  *SC dosing every 4 weeks 
  **200 mg SC every 2 weeks; 400 mg SC every 4 weeks 
Table 5. Pivotal Phase III Trials for Other Treatment Options in Psoriatic Arthritis  
 Reference Study 
Size 
(n) 
 
Doses (vs Placebo) % Achieving 
ACR20 Response 
(tx/placebo) (wk) 
% Achieving 
PASI75 Response 
(tx/placebo) (wk) 
 
Less Radiographic 
Progression 
Apremilast Palace 1 
[104] 
504 30 mg bid/20 mg bid 
 
38.1/30.4/19 (16) 
 
21/17.6/4.6(24) 
 
Not assessed 
 Palace 2 
[105] 
484 30 mg bid/20 mg bid 
 
32.1/37.4/18.9 (16) 
 
22.1/18.8/2.7 (16) 
 
Not assessed 
 Palace 3 
[106] 
505 30 mg bid/20 mg bid 
 
41/28/18 (16) 
 
21/20/8 (16) 
 
Not assessed 
 Palace 4 
[107] 
527 30 mg bid/20 mg bid 
 
32.3/29.2/16.9 (16) 
 
- Not assessed 
Secukinumab Future 1 
[110] 
606 75 mg1/150 mg 1 
 
50.5/50/17.3 (24) 
 
 
64.8/61.1/8.3 (24) 
 
wk 24 and wk 52 
 
 Future 2 
[111] 
397 300 mg2/150 mg2/75 mg2 
 
54/51/29/15 (24) 63/48/ 28 (not 
sig)/16 (24) 
 
Not assessed 
Ustekinumab3 PSummit-1 
[113,115] 
615 90mg/45mg 
 
49.5/42.4/22.8 (24) 
 
62.4/57.2/11 (24) wk 24 and 2 yrs  
 PSummit-2 
[114,116] 
312 90mg/45mg 
 
43.8/43.7/20.2 (24) 
 
55.6/51.3/5 (24) 
 
wk 24 and 1 yr 
 
1placebo or IV loading doses 10 mg/kg at baseline, week 2, and week 4 and then SC every 4 weeks 
2SC loading doses 300 mg, 150mg, 75 mg, or placebo once a week from baseline to week 4 and then SC every 4 weeks 
3placebo, 45 mg or 90 mg SC at baseline and 4 weeks and then every 12 weeks  
ACR20, American College of Rheumatology 20% improvement criteria; bid, twice a day; IV, intravenous; PASI75,  75% 
improvement in Psoriasis Area and Severity Index; SC, subcutaneous; tx, treatment; wk, week; yrs, years 
 
 
Table 6. Medications in Development for PsA 
Drug Mechanism of Action Current Phase in 
Clinical Trials 
Ixekizumab IL-17A inhibitor 
 
SPIRIT-P2 Phase III 
(NCT02349295) 
 
Abatacept 
 
CTLA4-Ig phase III 
(NCT01860976) 
 
Risankizumab 
 
IL-23 inhibitor 
 
phase II 
(NCT02986373) 
 
Guselkumab IL-23 inhibitor 
 
phase II 
(NCT02319759) 
 
Tofacitinib Oral JAK inhibitor 
 
phase III 
(NCT01976364) 
 
Tildrakizumab 
 
IL-23 inhibitor 
 
Unknown currently 
 
 
CTLA4-Ig, cytotoxic T lymphocyte associated antigen-4 immunoglobulin fusion protein 
 
 
 
 
 
